Global Ankylosing Spondylitis (AS) Market: Rising Cases of Ankylosing Spondylitis Augments the Market Growth

Global Ankylosing Spondylitis (AS) Market

Ankylosing Spondylitis is an inflammatory disease that can cause problems in spine. This usually causes inflammation in spine which can cause chronic pain and discomfort. It can also fuse vertebrae in the spine which can make the spine less flexible. In some cases this also can form new bone in the spine which can cause sections of the spine to fuse in an immobile or fixed position. This disease is most likely to be occurred in the people with gene called HLA- B27. This condition can cause some other complications such as eye inflammation, heart problems, compression fractures and other. Practically there is no cure for this condition but some medication and treatment can be done so that there sign and symptoms can be reduced. Different drugs such as TNF blockers, anti- inflammatory drugs, immunosuppressive drugs, nonsteroidal anti- inflammatory drugs and other are given to the patient with this condition.

Access Full Report at https://www.databridgemarketresearch.com/reports/global-ankylosing-spondylitis-as-market

Some of the factors responsible for the growth of this market are as follow:

• Increasing cases of ankylosing spondylitis worldwide: Ankylosing spondylitis (AS) is a form of arthritis that causes painful inflammation in the body, usually focused in the back and buttocks. With time, pain and inflammation can be spread in other part of the body such as hips, heals, large joints and other. If not treated on time, this can create many serious conditions such as eye problem, tiredness, osteoporosis, gastrointestinal disorders, conduction problem, aortic valve disease, cauda equine syndrome and other. This condition is very common among men as compared to the women and start showing its signs and symptom in adulthood
• Increasing number of population looking forward to solution for ankylosing spondylitis: The main aim of the treatment is to provide relieve from stiffness and pain. This treatment is mainly successful before it causes any damage to the joint. This condition cannot be cured but can be treated with medications such as naproxen, indomethacin, TNF blockers such as infliximab, etanercept, certolizumab pegol and other. They have the ability to help the patient to reduce the pain, tender, swollen joint, & other so they can get some comfort. Physical therapy is an significant component of treatment and can offer many advantages, ranging from pain relief to increased strength and flexibility. The incidence of ankylosing spondylitis is observed in around 0.1% to 0.5% of the world's adult population

The global ankylosing spondylitis (AS) market is segmented on the basis of drug type as nonsteroidal anti-inflammatory drugs, tnf blockers, immunosuppressive drugs, anti-inflammatory drugs, steroids, jak inhibitors, and others; application as juveniles, & adults; molecule as biologics, biosimilars,& small molecules and route of administration as parenteral, and oral.

Some of the launches and acquisition in the market are as follow:

• In August 209, Eli Lilly and Company announced that they have received approval from the FDA for their Taltz (ixekizumab) injection 80 mg/mL which is specially designed for the adults with active ankylosing spondylitis. This approval will help the patients so that they can get relive from the pain of the AS and will provide them with better treatment
• In January 2016, Novartis announced that they have received approval from the FDA for their Cosentyx which is specially designed for the treatment of adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).  This new approval has the ability to decrease the sign and symptoms of both AS & PsA and will help the patients so they can do their day to day activities easily

 “According to Data Bridge Market Research, global ankylosing spondylitis market is set to witness a substantial CAGR in the forecast period of 2019 to 2026”

Few of the major competitors currently working in the global ankylosing spondylitis (AS) market are Merck & Co., Inc., AbbVie Inc., Reliance Life Sciences., Xian Janssen Pharmaceutical Ltd., Momenta Pharmaceuticals, Sandoz International GmbH, Pfizer Inc., Amgen Inc., Regeneron Pharmaceuticals, CELGENE CORPORATION, Trinity Biotech Ireland, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd., Celltrion Inc., Boehringer Ingelheim International GmbH, Hetero, Izana Bioscience and others

Today, many people are demanding for the treatment of this ankylosing spondylitis as it causes them pain and discomfort. Government is also taking many different steps and initiatives so they can provide better healthcare infrastructure. Many different medications are available in the market for the treatment of this disease.